Composing compound libraries for hit discovery-rationality-driven preselection or random choice by structural diversity?

Future Medicinal Chemistry

Volumn 6, Issue 18, 2014, Pages 2057-2072

  Weidel, Elisabeth ^a   Negri, Matthias ^a   Empting, Martin ^a   Hinsberger, Stefan ^a   Hartmann, Rolf W ^a,b  

^a SAARLAND UNIVERSITY   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN INHIBITOR; RECOMBINANT PROTEIN; BACTERIAL PROTEIN; MOLECULAR LIBRARY; PROTEIN BINDING;

ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; ENZYME INHIBITION; IMMOBILIZATION; MOLECULAR LIBRARY; PHARMACOPHORE; PROTEIN BINDING; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; DRUG SCREENING; ESCHERICHIA COLI; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE;

BACTERIAL PROTEINS; BINDING SITES; DRUG EVALUATION, PRECLINICAL; ESCHERICHIA COLI; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE;

EID: 84919783644     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.142     Document Type: Article

References (47)

1. Levy SB, Marshall B. Antibacterial resistance worldwide: causes, challanges and respones. Nat. Med. 10(12), S122-S129 (2004
2. Kaitin KI, Dimasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 89(2), 183-188 (2011
3. Talbot GH. What is in the pipeline for Gram-negative pathogens?. Expert Rev. Anti Infect. Ther. 6(1), 39-49 (2008
4. Livermore DM.Has the era of untreatable infections arrived?. J. Antimicrob. Chemother. 64(4), 29-36 (2009
5. Lambert PA. Mechanism of antibiotic resistance in Pseudomonas aeruginosa. J. R. Soc. Med. 95, 22-26 (2002
6. Nikaido H. Prevention of drug access to bacterial targets -permeability barriers and active efflux. Science. 264(5157), 382-388 (1994
7. Rivers EC, Mancera RL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today 13(23-24), 1090-1098 (2008
8. Barrett CT, Barrett JF. Antibacterials: are the new entries enough to deal with the emerging resistance problems?. Curr. Opin. Biotechnol. 14(6), 621-626 (2003
9. Fischbach MA, Welsh CT. Antibiotics for emerging pathogens. Science 325(5944), 1089-1093 (2009
10. Gallant P, Finn J, Keith D, Wendler P. The identification of quality antibacterial drug discovery targets: a case study with aminoacyl-tRNA synthetases. Expert Opin. Ther. Targets 4(1), 1-9 (2000
11. Navratilova I, Hopkins AL. Fragment screening by surface plasmon resonance. ACS Med. Chem. Lett. 1(1), 44-48 (2010
12. Wielens J, Headey SJ, Rhodes DI et al. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?. J. Biomol. Screen. 18(2), 147-159 (2013
13. Siegal G, Ab E, Schultz J. Integration of fragment screening and library design. Drug Discov. Today 12(23-24), 1032-1039 (2007
14. Mayr LM, Bojanic D. Novel trends in high-throughput screening. Curr. Opin. Pharmacol. 9(5), 580-588 (2009
15. Valler MJ, Green D. Diversity screening versus focussed screening in drug discovery. Drug Discov. Today 5(7), 286-293 (2000
16. Walters WP, Stahl MT, Murcko MA. Virtual Screening - an overview. Drug Discov. Today 3(4), 160-178 (1998
17. Marriott DP, Dugall IG, Meghani P, Liu YJ, Flower DR. Lead generation using pharmacophore mapping and threedimensional database searching: application to muscarin M(3) receptor antagonists. J. Med. Chem. 42(17), 3210-3216 (1999
18. Boucher HW, Talbot GH, Bradley JS et al. Bad bugs, no drugs: no eskape! An update from infectious diseases society of America. Clin. Infect. Dis. 48(1), 1-12 (2009
19. Storz MP, Maurer CK, Zimmer C et al. Validation of PqsD as an anti-biofilm target in Pseudomonas aeruginosa by development of small-molecule inhibitors. JACS 134(39), 16143-16146 (2012
20. Alhamadsheh MM, Waters NC, Sachdeva S, Lee P, Reynolds KA. Synthesis and biological evaluation of novel sulfonylnaphtalene-1, 4-diols as FabH inhibitors. Bioorg. Med. Chem. Lett. 18(24), 6402-6405 (2008
21. Daines RA, Pendrak I, Sham K et al. First x-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. J. Med. Chem. 46(1), 5-8 (2003
22. Al-Balas Q, Anthony NG, Al-Jaidi Bet al. Identification of 2-Aminothiazole-4-carboxylate derivates active against Mycobacterium tuberculosis H37Rv and the beta-keto-ACP synthase mtFabH. PloS ONE 4(5), e5617 (2009
23. Senior SJ, Illarionova PA, Gurcha SS et al. Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme. Bioorg. Med. Chem. Lett. 13(21), 3685-3688 (2003
24. Kim P, Zhang YM, Shenoy G et al. Structure-Activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli. J. Med. Chem. 49(1), 159-171 (2006
25. Nie Z., Perretta C, Lu J et al. Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-Acyl carrier protein synthase III as potential antimicrobial agents. J. Med. Chem. 48(5), 1596-1609 (2005
26. Bera AK, Atanasova V, Robinson H et al. Structure of PqsD, a Pseudomonas quinolone signal biosynthetic enzyme, in complex with anthranilate. Biochem. 48(36), 8644-8655 (2009
27. Weidel E, De Jong JC, Brengel C et al. Structure optimization of 2-benzamidobenzoic acids as PqsD inhibitors for Pseudomonas aeruginosa infections and elucidation of binding mode by SPR, STD NMR, and molecular docking. J. Med. Chem. 56(15), 6146-6155 (2013
28. Storz MP, Brengel C, Weidel E et al. Biochemical and biophysical analysis of a chiral PqsD inhibitor revealing tight-binding behavior and enantiomers with contrary thermodynamic signatures. ACS Chem. Biol.8(12), 2794-2801 (2013
29. Davies C, Heath RJ, White SW, Rock CO. The 1.8 angstrom crystal structure and active-site architecture of beta-ketoacylacyl carrier protein synthase III (FabH) from Escherichia coli . Structure 8(2), 185-195 (2000
30. Pistorius D, Ullrich A, Lucas S, Hartmann RW, Kazmaier U, Müller R. Biosynthesis of 2-Alkyl-4(1H)-quinolones in Pseudomonas aeruginosa: potential for therapeutic interference with pathogenicity. Chembiochem 12(6), 850-853 (2011
31. Henn C, Boettcher S, Steinbach A, Hartmann RW. Catalytic enzyme activity on a biosensor chip: combination of surface plasmon resonance and mass spectrometry. Anal. Biochem 428(1), 28-30 (2012
32. Zhang JH, Chung TDY, Oldenburg KR. A simple statistic parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4(2), 67-73 (1999
33. Jones G, Willett P, Glen RC, Leach AR, Taylor R, Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267(3), 727-748 (1997
34. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 52(4), 609-623 (2003
35. Molecular Operating Environment (MOE)2010.10. Chemical Computing Group, Quebec, Canada (2010
36. Perspicace S, Banner D, Benz J, Müller F, Schlatter D, Huber W. Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen. 14(4), 337-349 (2009
37. Giannetti AM, Koch BD, Browner MF. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J. Med. Chem. 51(3), 574-580 (2008
38. Rees DC, Congreve M, Murray CW, Carr R. Fragmentbased lead discovery. Nat. Rev. Drug Discov. 3(8), 660-672 (2004
39. Yuan YQ, Leeds JA, Meredith TC. Pseudomonas aeruginosa directly shunts beta-oxidation degradation intermediates into de novo fatty acid biosynthesis. J. Bacteriol. 194(19), 5185-5196 (2012
40. Yuan YQ, Sachdeva M, Leeds JA, Meredith TC. Fatty acid biosynthesis in Pseudomonas aeruginosa is initiated by the FabY class of beta-ketoacyl acyl carrier protein synthases. J. Bacteriol. 194(19), 5171-5184 (2012
41. Shelat AA, Guy RK. Scaffold composition and biological relevance of screening libraries. Nat. Chem. Biol. 3(8), 442-446 (2007
42. Hann MM, Leach AR, Harper G. Molecular complexity and its impact on the probability of finding leads for drug discovery . J. Chem. Inf. Comput. Sci. 41(3), 856-864 (2001
43. Hopkins AL, Groom CR, Alex A. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today 9(10), 430-431 (2004
44. Howard S, Berdini V, Boulstridge JA et al. Fragment-based discovery of the pyrazol-4-yl-urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem. 52(2), 379-388 (2009
45. Villemagno B, Flipo M, Blondiaux N et al. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging and linking approaches. J. Med. Chem. 57(11), 4876-4888 (2014
46. Johnson CN, Berdini V, Beke L et al. Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase. J. Med. Chem. Lett. (2014) (Epub ahead of print
47. Sahner JH, Brengel C, Storz MP et al. Combining in silico and biophysical methods for the development of Pseudomonas aeruginosa quorum sensing inhibitors: an alternative approach for structure-based drug design. J. Med. Chem. 56(21), 8656-8664 (2013